- Sabrina Corazza, Director of Business Development, Axxam
- Philip Gribbon, Ph.D., Assistant Head of Department, Fraunhofer IME ScreeningPort
The track will focus on emerging targets and mechanisms including protein degradation, non-coding RNA’s and stabilising PPI’s. The therapeutic exploitation of intrinsic celluar functions including proteolysis pathways, autophagy and lysosomal degredation mechanisms will be explored. Leading experts in disease biology will present new strategies for identifying, investigating and validating challenging target mechanisms in case studies. Sessions will cover the process of translating biological insight into tractable assays, efficient tool compounds and biologicals, and methods for generating attractive starting points for drug discovery programmes.
The technology track covers recent technological innovations which promise to significantly enhance our understanding of disease-related mechanisms and eventually lead to fundamental improvements in the practice of drug discovery. The session on super- resolution microscopy will explore its emergence from basic research applications towards exciting new application in industrial scale screening of biological events, at unparalleled sub-cellular scales. The real world application of artificial intelligence methods in target identification and therapeutic discovery will be presented by key leaders in the field from Pharma and Biotech. The session on fragment screening will focus on library design and compound elaboration, as well as the increased use of information rich endpoints including high throughput X-ray crystallography.
In the Discovery track, new approaches to identifying attractive hits, confirming target engagement, progressing leads and selecting disease relevant candidates for new and established targets will be illustrated in detailed case studies. A session on precision medicine will cover quantitative, high-throughput approaches for using primary patient material, cellular models and complex tissues and how such patient insights can drive translation between disease insight and clinical application. Finally, innovative technologies for monitoring target engagement as well as downstream biological consequences will be showcased and their impact on increasing understanding of molecular selectivity and mode of action explored.
How can we be competitive innovative and creative in pitching a brilliant idea, bringing a new product on the market or effectively translating a great research result into a successful start-up? The focus of this track is to provide insights in each of these topics trying to answer some questions and stimulating new ones. Don’t miss the opportunity of being part of the audience.